Regenxbio (RGNX) shares were down 7.5% in recent Tuesday trading after Goldman Sachs downgraded the stock to neutral from buy, and trimmed the price target to $14 from $38.
Trading volume stood at roughly 661,000 shares, compared with the daily average of more than 1.3 million shares.
Price: 7.30, Change: -0.59, Percent Change: -7.48